Jazz Drug Patent Portfolio
Jazz owns 3 orange book drugs protected by 26 US patents Given below is the list of Jazz's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11426373 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 19 Sep, 2037 | Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US11986446 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US10195168 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders | 11 Jan, 2033 | Active |
| US10675258 | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders | 11 Jan, 2033 | Active |
| US11554102 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders | 11 Jan, 2033 | Active |
| US8591922 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 11 Jan, 2033 | Active |
| US8901173 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 11 Jan, 2033 | Active |
| US9132107 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 11 Jan, 2033 | Active |
| US7763615 | Ecteinascidin analogs for use as antitumour agents | 13 Dec, 2029 | Active |
| US8731963 | Sensitive drug distribution system and method | 17 Jun, 2023 | Expired |
| US8731963 | Sensitive drug distribution system and method | 17 Dec, 2022 | Expired |
| US6024981 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6221392 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6106861 | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth | 05 Dec, 2017 | Expired |
Latest Legal Activities on Jazz's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Jazz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864181 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Apr, 2024 | US9486426 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Nov, 2023 | US10675258 |
|
Patent Term Extension Certificate
Critical
| 17 Oct, 2023 | US7763615 |
|
Electronic Review
Critical
| 06 Jun, 2023 | US7763615 |
| Notice of Final Determination -Eligible | 15 May, 2023 | US7763615 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Mar, 2023 | US9132107 |
| Notice of Final Determination -Eligible | 25 Jan, 2023 | US7763615 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Jan, 2023 | US11554102 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Jan, 2023 | US11554102 |
|
Email Notification
Critical
| 29 Dec, 2022 | US11554102 |
|
Issue Notification Mailed
Critical
| 28 Dec, 2022 | US11554102 |
|
Application Is Considered Ready for Issue
Critical
| 13 Dec, 2022 | US11554102 |
| Dispatch to FDC | 13 Dec, 2022 | US11554102 |
|
Issue Fee Payment Verified
Critical
| 12 Dec, 2022 | US11554102 |
Jazz's Drug Patent Litigations
Jazz's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 06, 2015, against patent number US8772306. The petitioner Par Pharmaceutical, Inc., challenged the validity of this patent, with Jazz Pharmaceutical, Inc. as the respondent. Click below to track the latest information on how companies are challenging Jazz's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8731963 | September, 2015 |
Final Written Decision
(22 Mar, 2017)
| Jazz Pharmaceuticals, Inc. | Par Pharmaceutical, Inc. et al. |
| US8772306 | February, 2016 |
Terminated-Denied
(28 Jul, 2016)
| Jazz Pharmaceutical, Inc. | Amneal Pharmaceuticals LLC |
| US8772306 | October, 2015 |
Terminated-Settled
(23 May, 2016)
| Jazz Pharmaceutical, Inc. | Ranbaxy, Inc. |
| US9050302 | March, 2016 |
Terminated-Denied
(23 May, 2016)
| Jazz Pharmaceuticals Ireland Limited | RANBAXY INC |
| US8772306 | October, 2015 |
Terminated-Denied
(12 Apr, 2016)
| Jazz Pharmaceutical, Inc. | Par Pharmaceutical, Inc. |
Jazz Drug Patents' Oppositions Filed in EPO
Jazz drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 23, 2018, by Hoffmann Eitle. This opposition was filed on patent number EP14709858A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17200764A | Sep, 2020 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP17200764A | Sep, 2020 | Hexal AG | Granted and Under Opposition |
| EP17200764A | Sep, 2020 | Zentiva, k.s. | Granted and Under Opposition |
| EP17200764A | Mar, 2020 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Granted and Under Opposition |
| EP14709858A | Aug, 2018 | Hexal AG | Revoked |
| EP14709858A | Aug, 2018 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Revoked |
| EP14709858A | Jul, 2018 | Hoffmann Eitle | Revoked |
Jazz's Family Patents
Jazz drugs have patent protection in a total of 30 countries. It's US patent count contributes only to 24.4% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Jazz Drug List
Given below is the complete list of Jazz's drugs and the patents protecting them.
1. Fazaclo Odt
Fazaclo Odt is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
| US6106861 | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth |
05 Dec, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fazaclo Odt's drug page
2. Xywav
Xywav is protected by 22 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11426373 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
19 Sep, 2037
(12 years from now)
| Active |
| US10213400
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(8 years from now)
| Active |
| US10864181
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(8 years from now)
| Active |
| US11253494
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(8 years from now)
| Active |
| US8772306
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(8 years from now)
| Active |
| US9050302
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(8 years from now)
| Active |
| US9486426
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(8 years from now)
| Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US11986446 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(8 years from now)
| Active |
| US10195168 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
11 Jan, 2033
(8 years from now)
| Active |
| US10675258 | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders |
11 Jan, 2033
(8 years from now)
| Active |
| US11554102 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
11 Jan, 2033
(8 years from now)
| Active |
| US8591922 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
11 Jan, 2033
(8 years from now)
| Active |
| US8901173 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
11 Jan, 2033
(8 years from now)
| Active |
| US9132107 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
11 Jan, 2033
(8 years from now)
| Active |
| US8731963
(Pediatric)
| Sensitive drug distribution system and method |
17 Jun, 2023
(1 year, 6 months ago)
| Expired |
| US8731963 | Sensitive drug distribution system and method |
17 Dec, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xywav's drug page
3. Zepzelca
Zepzelca is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7763615 | Ecteinascidin analogs for use as antitumour agents |
13 Dec, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepzelca's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List